在ADC火热的当下,作为ADC领域的三大上市生物医药企业,随着2024年财报揭晓,这三家业绩情况也成为观测行业风向的绝佳窗口。下面将围绕2024年度的业绩情况、海外布局、研发投入、研发人均薪酬等情况分析这几家企业的发展战略布局。业绩及净利润盘点作为企业经营的"年度体检报告",营业收入不仅折射出创新药企的生存逻辑,也反应出企业的发展规划。从营收数据情况来看,百利天恒营收独占鳌头58.22亿元,同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.